Home / About Peptonic
 

About Peptonic

PEPTONIC Medical is commercializing VagiVital™ – a hormone free treatment for vaginal atrophy (VA). The product is a vaginal gel for topical administration.

Our vision is to offer safe and effective treatments for women suffering from vaginal atrophy during menopause and after.

VagiVital™ has been studied in randomized, double-blind and placebo controlled clinical trials. The product has shown positive effects on both objective (vaginal pH and proportion of superficial cells in the vaginal mucosa) and subjective signs (most bothersome symptoms, such as vaginal dryness, vaginal irritation/itching, dyspareunia and dysuria) of vaginal atrophy. It was very well tolerated and caused no serious adverse effects.

The pipeline of PEPTONIC Medical also includes Vagitocin®, which is an oxytocin-based vaginal gel for the treatment of VA. This product candidate is in clinical development phase 2. The development of Vagitocin® is on hold pending additional data on i.a. the mechanism of action.

In July 2014, PEPTONIC Medical was listed on the AktieTorget stock exchange (www.aktietorget.se, ticker: PMED) in Stockholm.

 

Recent Posts

Recent Comments

    Archives

    Categories

    Meta

    All press releases on Spotlightstockmarket.com

    All published press releases from PEPTONIC medical is available on spotlightstockmarket.com.

    About us

    PEPTONIC Medical is an innovative Swedish pharmaceutical company developing and commercializing safe and effective products for the treatment of menopausal symptoms, such as vaginal atrophy. VagiVital® is a registered trademark of PEPTONIC Medical. The product is being commercialised for the non-prescription use for the treatment of vaginal atrophy.

    The Company was founded in 2009 and its first candidate drug product is Vagitocin® – an estrogen-free oxytocin based product for the treatment of vaginal atrophy in clinical development phase 2.

    Oxytocin has a long history of safe and effective medical use and offers an alternative to estrogen and estrogen-like acting compounds for menopausal and postmenopausal women.